Liver peroxisome

Liver peroxisomes are multifunctional metabolic organelles essential for lipid homeostasis and oxidative detoxification within hepatocytes. They are the primary site for the alpha- and beta-oxidation of branched-chain and very long-chain fatty acids (VLCFAs), as well as the initial steps of bile acid and ether phospholipid (plasmalogen) biosynthesis. To manage the oxidative byproducts of these reactions, peroxisomes contain high concentrations of catalase and other antioxidant enzymes that sequester and degrade hydrogen peroxide. In a pharmacological context, liver peroxisomes are not a single molecular target but a cellular system regulated primarily by the nuclear receptor PPAR-alpha. Activation of this receptor by fibrate drugs leads to 'peroxisome proliferation' and upregulates fatty acid catabolism, which is utilized clinically to treat hypertriglyceridemia. Genetic defects in peroxisomal biogenesis or specific peroxisomal enzymes result in severe metabolic conditions, such as Zellweger syndrome and X-linked adrenoleukodystrophy, characterized by the toxic accumulation of VLCFAs and systemic organ failure. While peroxisome proliferation is strongly linked to hepatocarcinoma in rodent models, humans appear relatively resistant to this specific proliferative effect, making PPAR-alpha agonists a mainstay in lipid management. [Source: NIH/NCBI, PubMed, StatPearls]

Other names

Hepatic peroxisomeMicrobodyPeroxisome

Drugs such as fibrates act as agonists of the Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha), a transcription factor that induces the expression of genes involved in peroxisomal beta-oxidation and stimulates the proliferation of liver peroxisomes to enhance lipid clearance.